Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Shepherd

Showing results (1241-1250 of 1,281) with videos related to

Pageof 129
Sort By:
The American Journal of Clinical Nutrition|February 16, 2023
Monitoring body composition change for intervention studies with advancing 3D optical imaging technology in comparison to dual-energy X-ray absorptiometryMichael C Wong, Jonathan P Bennett, Lambert T Leong, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2007
Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safetyTimothy I Richardson, Scott A Frank, Minmin Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2004
Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonistBrenda L Palucki, Min K Park, Ravi P Nargund, et al.
JAMA Network Open|July 25, 2023
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical TrialMiguel García-Pardo, Kasia Czarnecka-Kujawa, Jennifer H Law, et al.
Scientific Reports|October 20, 2018
Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine modelsHarold B Brooks, Timothy I Meier, Sandaruwan Geeganage, et al.
The American Journal of Clinical Nutrition|August 3, 2025
Methodological standards for body composition-an expert-endorsed guide for research and clinical applications: levels, models, and terminologyCarla M Prado, M Cristina Gonzalez, Kristina Norman, et al.
JAMA Oncology|April 10, 2020
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical TrialNaiyer A Rizvi, Byoung Chul Cho, Niels Reinmuth, et al.
FEBS Open Bio|February 12, 2026
Applicability of mitotic figure counting by deep learning: a development and pan-cancer validation studyJoakim Kalsnes, Maria X Isaksen, Frida Julbø, et al.
Nature Communications|January 3, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trialApril A N Rose, Jennifer Maxwell, Emmanuelle Rousselle, et al.
Pageof 129

Showing results (1241-1250 of 1,281) with videos related to

Sort By:
Pageof 129
The American Journal of Clinical Nutrition|February 16, 2023
Monitoring body composition change for intervention studies with advancing 3D optical imaging technology in comparison to dual-energy X-ray absorptiometryMichael C Wong, Jonathan P Bennett, Lambert T Leong, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2007
Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safetyTimothy I Richardson, Scott A Frank, Minmin Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2004
Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonistBrenda L Palucki, Min K Park, Ravi P Nargund, et al.
JAMA Network Open|July 25, 2023
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical TrialMiguel García-Pardo, Kasia Czarnecka-Kujawa, Jennifer H Law, et al.
Scientific Reports|October 20, 2018
Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine modelsHarold B Brooks, Timothy I Meier, Sandaruwan Geeganage, et al.
The American Journal of Clinical Nutrition|August 3, 2025
Methodological standards for body composition-an expert-endorsed guide for research and clinical applications: levels, models, and terminologyCarla M Prado, M Cristina Gonzalez, Kristina Norman, et al.
JAMA Oncology|April 10, 2020
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical TrialNaiyer A Rizvi, Byoung Chul Cho, Niels Reinmuth, et al.
FEBS Open Bio|February 12, 2026
Applicability of mitotic figure counting by deep learning: a development and pan-cancer validation studyJoakim Kalsnes, Maria X Isaksen, Frida Julbø, et al.
Nature Communications|January 3, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trialApril A N Rose, Jennifer Maxwell, Emmanuelle Rousselle, et al.
Pageof 129